Ganglioneuroblastoma — Research

Ganglioneuroblastoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	468	`("Ganglioneuroblastoma"[mh] OR "Ganglioneuroblastomas"[mh])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	73	`("Ganglioneuroblastoma"[mh] OR "Ganglioneuroblastomas"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	14	`("Ganglioneuroblastoma"[mh] OR "Ganglioneuroblastomas"[mh]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (1)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed